![]() |
|
|
Vol. 30, Issue 5, 531-533, May 2002
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| |
Abstract |
|---|
|
|
|---|
Linoleic acid has recently been shown to be glucuronidated in vitro by human liver and intestinal microsomes and recombinant UGT2B7. In the present study, the dietary fatty acids (FA), phytanic acid (PA), and docosahexaenoic acid (DHA) have been used as substrates for human UDP-glucuronosyltransferases (UGTs). Both compounds were effectively glucuronidated by human liver microsomes (HLM; 1.25 ± 0.36 and 1.12 ± 0.32 nmol/mg × min for PA and DHA, respectively) and UGT2B7 (0.71 and 0.53 nmol/mg × min). Kinetic analysis produced relatively low Km values for PA with both HLM and UGT2B7 (149 and 108 µM, respectively). The Km for DHA glucuronidation by HLM (460 µM) was considerably higher than that for UGT2B7 (168 µM), suggesting the involvement in microsomes of other UGT isoforms in addition to UGT2B7. Glucuronidation of PA and DHA by gastrointestinal microsomes from 16 human subjects was determined. In general, both PA and DHA were glucuronidated by gastric and intestinal microsomes, and activity toward both substrates was lowest in the stomach, increased in the small intestine, and lower in the colon. However, there were large interindividual variations in UGT activity toward both substrates in all segments of the intestine, as has been seen with other substrates. Thus, PA and DHA are effective in vitro substrates for human liver, gastric and intestinal microsomes, and glucuronidation may play a role in modulating the availability of these FA as ligands for nuclear receptors.
| |
Introduction |
|---|
|
|
|---|
FA1
are important structural components of cell membranes, sources of
energy, and precursors of eicosanoids. There is growing evidence
supporting a role for FA in the modulation of cell-signaling pathways
(Hwang and Rhee, 1999
). Several recent studies have indicated that FA,
such as PA and DHA (structures shown in Fig.
1), activate the retinoid X (RXR) and
peroxisome proliferator-activated (PPAR) nuclear receptors. PA is a
branched-chain FA that is a constituent of dairy products, meat, and
fish. Kitareewan et al. (1996)
and Lemotte et al. (1996)
simultaneously
carried out studies that showed that PA and other phytol derivatives
activate RXR. It has recently been shown that PA is also a naturally
occurring ligand for PPAR
(Zomer et al., 2000
). DHA is a constituent
of the human diet, particularly fatty fish, and plays physiological
roles in brain maturation and development and retina development (de
Urquiza et al., 2000
; Kastner et al., 1994
). Studies have demonstrated that DHA is a highly specific ligand for RXR
in mouse brain (de Urquiza et al., 2000
), and DHA has been reported as a ligand for PPAR
(Keller et al., 1993
).
|
Although glucuronides of medium-chain and oxidized long-chain FA have
been identified as being excreted in human urine (Duran et al., 1985
;
Kuhara et al., 1986
; Costa et al., 1996
; Street et al., 1996
; Sacerdoti
et al., 1997
), only recently has glucuronidation of FA been
demonstrated in vitro with human liver and intestine (Jude et al.,
2000
, 2001a
,b
). In the current studies, we investigated the
glucuronidation of PA and DHA by human liver and intestinal microsomes
and recombinant UGT2B7, which has been shown to glucuronidate linoleic
acid (LA; cis-9,12-octadecadienoic acid) and its oxidized derivatives (Jude et al., 2001a
,b
). The results showed that both PA and
DHA were effectively glucuronidated in vitro by human liver and
intestinal microsomes and UGT2B7.
| |
Materials and Methods |
|---|
|
|
|---|
PA, DHA, UDP-glucuronic acid (UDPGA), saccharolactone, and HEPES were obtained from Sigma Chemical Co. (St. Louis, MO). [Glucuronyl-14C]UDPGA ([14C]UDPGA) was from PerkinElmer Life Sciences (Boston, MA). Solvents for thin layer chromatography were all high-pressure liquid chromatography grade (Fisher Scientific, Houston, TX). All other reagents were of the highest purity available.
Human Liver Microsomes and Human Recombinant UGT2B7.
Human liver and gastrointestinal microsomes were prepared as previously
described (Jude et al., 2001b
) from tissue from organ donors obtained
by transplant surgeons at University Hospital (Little Rock, AR)
according to a protocol approved by the Human Research Advisory
Committee of the University of Arkansas for Medical Sciences. HK293
cells expressing UGT2B7, prepared as previously described (Coffman et
al., 1997
), were a gift from Dr. T. Tephly, Department of Pharmacology
(University of Iowa, Des Moines, IA). A membrane fraction enriched in
UGT2B7 was prepared as described by Battaglia et al. (1994)
, and
aliquots were stored at
80°C until used. Dr. Tephly also supplied
membrane fractions enriched in human UGT1A8 and UGT1A10.
Enzyme Assays.
UGT activities were determined as described in detail previously
(Radominska-Pyrek et al., 1986
, 1987
) using
[14C]UDPGA as the sugar donor, 100 µM PA and
DHA as substrates, and 50 µg of microsomal protein, with incubation
at 37°C for 10 to 30 min. PA and DHA were prepared as micelles with
Brij 58, which served to both solubilize the substrates and activate
UGTs. Kinetic analysis was carried out at a constant UDPGA
concentration (4 mM), with substrate concentrations from 25 to 750 µM
and an incubation time of 10 min. Kinetic parameters were determined
using EnzymeKinetics software (Trinity Software, Compton, NH).
-glucuronidase hydrolysis, after the standard assay procedure,
duplicate reactions were stopped with 1 ml of 0.1 M
glycine-trichloroacetic acid, pH 2.8, and samples were applied to
BondElut C18 cartridges (Varian, Palo Alto, CA)
primed as recommended by the manufacturer. The cartridges were washed
with glycine-trichloroacetic acid (5 ml) and water (5 ml) and eluted
with methanol (3 ml); the methanol was evaporated. For each set of
duplicate samples, one was dissolved in 30 mM sodium phosphate buffer,
pH 7.4, containing 50 units of Escherichia coli
-glucuronidase, and the other sample was dissolved in buffer alone
(60 µl). Both samples were incubated for 4 h at 37°C after
which reactions were stopped with ethanol. The samples were then
handled as for a standard assay.
| |
Results and Discussion |
|---|
|
|
|---|
The results of assays of enzymatic activity toward PA and DHA with
HLM and UGT2B7 demonstrated that both PA and DHA were good substrates
for microsomal UGTs and UGT2B7. The UGT activities toward each
substrate were similar for each protein source (PA: 1250 ± 357 and 1119 ± 320 pmol/mg of protein × min for HLM2 and UGT2B7, respectively; DHA: 710 ± 122 and 533 ± 87 pmol/mg
of protein × min for HLM2 and UGT2B7, respectively) and are
within the same range as those found in our laboratory for other FA
(Jude et al., 2000
, 2001a
,b
). As with other FA, the activity toward
both PA and DHA was significantly higher with HLM than with UGT2B7,
suggesting that UGT isoforms other than UGT2B7 are involved in the
glucuronidation of these FA. Human recombinant UGT1A8 and UGT1A10,
intestine-specific isoforms, had no measurable activity toward PA or
DHA.
To confirm that the polar metabolites were indeed glucuronides, PA and
DHA were incubated with HLM2 under standard assay conditions, and the
products were partially purified on C18
cartridges, followed by incubation at 37°C in absence or presence of
-glucuronidase. There was significant activity in the absence of
-glucuronidase (1410 and 994 pmol/mg × min for PA and DHA,
respectively). However, following
-glucuronidase hydrolysis, there
was no detectable activity with either substrate. Since the only
functional group in these compounds available for conjugation is the
carboxyl group, these metabolites are carboxyl-linked glucuronides,
which have also been identified for LA and 13-hydroxyoctadecadienoic
acid (Jude et al., 2001a
).
Kinetic analysis (Table 1) showed that
the apparent Km values for
glucuronidation of PA by HLM2 and UGT2B7 were similar, but the
Vmax for HLM2 was more than twice that
of UGT2B7. These values are very similar to those found previously for
LA (Jude et al., 2001a
). With DHA, the
Km for UGT2B7 was more than 2 times lower than that for HLM2, reinforcing the inference from the enzymatic assays that more than one UGT isoform is involved in the microsomal glucuronidation of DHA. The DHA Vmax
with HLM2 was 4 times higher that than found with UGT2B7. Despite the
variations in Km and Vmax, the efficiencies of the
reactions
(Vmax/Km)
were similar, varying over only a 2-fold range.
|
We have shown previously that LA and its hydroxylated derivatives,
LA-9,10-diol and LA-12,13-diol, are glucuronidated by human intestinal
microsomes (Jude et al., 2001b
). Since both PA and DHA are dietary FA
and are therefore exposed to the intestinal mucosa, we measured the
glucuronidation of these two compounds by microsomes from the stomach,
small intestine (in 4 segments), and colon of 16 human subjects (5 females and 11 males; not all segments were available for all
subjects). The results of these assays are presented in Fig.
2. Several things are apparent from these
data. First, there were very large interindividual variations in
activity toward both substrates, as has been demonstrated previously with LA and the LA diols (Jude et al., 2001b
), steroid hormones, retinoic acid, and 4-nitrophenol (Radominska-Pandya et al., 1998
; Czernik et al., 2000
). Second, although the mean glucuronidation levels
toward the two substrates were not, in general, hugely different, the
maximum activities were almost twice as high for PA as for DHA. The
lowest activity for both substrates was found in stomach. For PA,
glucuronidation generally increased somewhat from duodenum through S-3
and then decreased slightly in S-4, with an additional decrease in
colon. Glucuronidation of DHA was fairly constant from duodenum through
S-3 but decreased by about half in S-4, with another slight increase in
colon. Additionally, glucuronidation of both substrates by
gastrointestinal microsomes from a majority of the subjects was lower
than comparable values measured with liver microsomes.
|
Although intestinal glucuronidation levels for both substrates were
much lower than in liver microsomes, when the size of the intestine is
taken into account, these data indicate that there is likely to be
considerable first-pass metabolism of both PA and DHA in human
intestine. Recent work from several laboratories has shown that
drug-metabolizing enzymes are actively involved in protecting the
organism from absorption of harmful chemicals, both endogenous and
exogenous (Hall et al., 1999
; Lin et al., 1999
; Racissi et al., 1999
;
Schuetz and Schinkel, 1999
). The cytochromes P450 and UGTs work in
concert to biotransform toxic compounds into forms which are substrates
for the ATP-dependent transporters, such as P-glycoprotein,
multispecific organic anion transporter, and multidrug resistance 1, 2, and 3 (Schinkel, 1998
; Smit et al., 1998
), and thus can be excreted out
of the intestinal mucosa. This function would be especially important
in relation to dietary FA, such as PA and DHA. The active
glucuronidation of FA by intestinal UGTs may be involved in preventing
accumulation of excess FA by contributing to the excretion of
glucuronidated FA from the intestinal mucosa back into the lumen.
Additionally, it has been hypothesized that drug-metabolizing enzymes,
including UGTs, play a role in controlling concentrations of ligands
for nuclear receptors (Nebert, 1991
). Since PA and DHA are effective
ligands for RXR
and PPAR
within the cell, glucuronidation may
function to limit the availability of PA and DHA as ligands for nuclear receptors.
| |
Footnotes |
|---|
Received October 19, 2001; accepted January 24, 2002.
This research was supported in part by National Institutes of Health Grant DK56226 to A.R.-P.
Address correspondence to: Dr. Anna Radominska-Pandya, Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 516, Little Rock, Arkansas 72205. E-mail: radominskaanna{at}uams.edu
| |
Abbreviations |
|---|
Abbreviations used are: FA, fatty acids; PA, phytanic acid (3,7,11,15-tetramethylhexadecanoic acid); DHA, cis-4,7,10,13,16,19-docosahexaenoic acid; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; LA, linoleic acid (cis-9,12-octadecadienoic acid); UDPGA, UDP-glucuronic acid; UGT, UDP-glucuronosyltransferase; HLM, human liver microsomes.
| |
References |
|---|
|
|
|---|
-developmental function: convergence of RXR- and RAR-signaling pathways in heart and eye.
Cell
78:
987-1003[CrossRef][Medline].
-hydroxy bile acids by human liver microsomes.
J Clin Invest
80:
234-241.
.
J Lipid Res
41:
1801-1807This article has been cited by other articles:
![]() |
S. Chouinard, G. Pelletier, A. Belanger, and O. Barbier Isoform-Specific Regulation of Uridine Diphosphate-Glucuronosyltransferase 2B Enzymes in the Human Prostate: Differential Consequences for Androgen and Bioactive Lipid Inactivation Endocrinology, November 1, 2006; 147(11): 5431 - 5442. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Little, M. Kurkela, J. Sonka, S. Jantti, R. Ketola, S. Bratton, M. Finel, and A. Radominska-Pandya Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases J. Lipid Res., September 1, 2004; 45(9): 1694 - 1703. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gardner-Stephen, J.-M. Heydel, A. Goyal, Y. Lu, W. Xie, T. Lindblom, P. Mackenzie, and A. Radominska-Pandya HUMAN PXR VARIANTS AND THEIR DIFFERENTIAL EFFECTS ON THE REGULATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE GENE EXPRESSION Drug Metab. Dispos., March 1, 2004; 32(3): 340 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Wierzbicki, P. D. Mayne, M. D. Lloyd, D. Burston, G. Mei, M. C. Sidey, M. D. Feher, and F. B. Gibberd Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease J. Lipid Res., August 1, 2003; 44(8): 1481 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Girard, O. Barbier, G. Veilleux, M. El-Alfy, and A. Belanger Human Uridine Diphosphate-Glucuronosyltransferase UGT2B7 Conjugates Mineralocorticoid and Glucocorticoid Metabolites Endocrinology, June 1, 2003; 144(6): 2659 - 2668. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||